Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classement en actions
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Prix de l'action
$4.87
Capitalisation boursière
$4.36B
Changement (1 jour)
-5.47%
Changement (1 an)
-15.62%
Pays
CN
Échange Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Catégorie
Healthcare
Historique des divisions d’actions pour Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
L’action Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (symbole : 688336) a subi un total de 1 divisions.
La division la plus récente a eu lieu le Jun 18, 2026.
Une action 688336 achetée avant le Jun 18, 2026 équivaudrait aujourd’hui à 1.45 actions 688336.
La division la plus récente a eu lieu le Jun 18, 2026.
Une action 688336 achetée avant le Jun 18, 2026 équivaudrait aujourd’hui à 1.45 actions 688336.
Liste des divisions d’actions
| Année | Division | Multiplicateur | Multiplicateur cumulatif |
|---|---|---|---|
| 2026-06-18 | 29:20 | x1.45 | x1.45 |
Divisions d’actions d’entreprises similaires ou concurrentes
| Entreprise | Nombre de divisions d’actions | Multiplicateur cumulatif | Pays |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 1 | x100 |
BE
|
|
| 0 | - |
NL
|
